Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность и переносимость препарата Тарка у больных артериальной гипертензией (программа ТАНДЕМ)
Эффективность и переносимость препарата Тарка у больных артериальной гипертензией (программа ТАНДЕМ)
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007.
2. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43–52.
3. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.
4. Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.
5. Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
6. Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5.
7. Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579–603.
8. Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47–51.
9. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51–3.
10. Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13–26.
11. Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680–7.
12. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598–615.
13. Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849–56.
14. Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592–7.
2. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43–52.
3. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.
4. Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.
5. Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
6. Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5.
7. Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579–603.
8. Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47–51.
9. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51–3.
10. Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13–26.
11. Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680–7.
12. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598–615.
13. Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849–56.
14. Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592–7.
Авторы
И.Е.Чазова, Л.Г.Ратова
ФГУ РКНПК Росмедтехнологий, Москва
ФГУ РКНПК Росмедтехнологий, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.